ARTICLE | Company News
Xenon, Novartis obesity deal
September 20, 2004 7:00 AM UTC
Novartis (NVS; SWX:NOVN) received exclusive worldwide rights to develop Xenon Pharmaceuticals' small molecule inhibitors of stearoyl-CoA desaturase-1 (SCD1), an enzyme involved in fatty acid metabolis...